First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Authors:
- Benjamin J. SolomonBSBenjamin J. Solomon
- Tony MokTMTony Mok
- Dong-Wan KimDKDong-Wan Kim
- Yi-Long WuYWYi-Long Wu
- Kazuhiko NakagawaKNKazuhiko Nakagawa
- Tarek MekhailTMTarek Mekhail
- Enriqueta FelipEFEnriqueta Felip
- Federico CappuzzoFCFederico Cappuzzo
- Jolanda PaoliniJPJolanda Paolini
- Tiziana UsariTUTiziana Usari
- Shrividya IyerSIShrividya Iyer
- Arlene ReismanARArlene Reisman
Top Cited Papers
- 4 December 2014
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 371 (23) , 2167-2177
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on PemetrexedJournal of Thoracic Oncology, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Quality of life research within the EORTC—the EORTC QLQ-C30European Journal of Cancer, 2002
- The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trialsEuropean Journal of Cancer, 1994
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993